Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series.

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2025-02-21 DOI:10.1016/j.cllc.2025.02.013

Xiuning Le, Anna Eisert, Te-Chun Hsia, Nirmal Vivek Raut, Azura Ahmad, Oscar Siu Hong Chan, Charlotte De Bondt, David Farrugia, Patrizia Froesch, Maria González-Cao, Lizza Hendriks, Maximillian J Hochmair, Julien Mazieres, Hazel O'Sullivan, Sanjay Popat, Jens Samol, Anthonie J van der Wekken, Tsung-Ying Yang, Lye Mun Tho, Ulrike Himpe, Wei-Sen Lam, Kirsty Wai Chung Lee, Iacopo Petrini, Karin Berghoff, Niki Karachaliou, Kirti Joshi, Soetkin Vlassak, Gee-Chen Chang

引用次数: 0

查看原文本刊更多论文

替波替尼加EGFR酪氨酸激酶抑制剂治疗EGFR突变met改变的NSCLC患者：一个病例系列

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.